Stockpolly
Search
Earnings are out
NEUP · NASDAQ · Biotechnology

Neuphoria Therapeutics (NEUP)

Develops BNC210 for anxiety and trauma-related disorders through virtualized clinical development.

$3.75
At close−0.04 (−1.06%)
Watchlist

In millions of USD, except per-share figures

In millionsQ4 FY23Jun 2023Q1 FY24Sep 2023Q2 FY24Dec 2023Q3 FY24Mar 2024Q4 FY24Jun 2024Q1 FY25Sep 2024Q2 FY25Dec 2024Q3 FY25Mar 2025Q4 FY25Jun 2025Q1 FY26Sep 2025Q2 FY26Dec 2025Q3 FY26Mar 2026
Revenue0000010115−10000
Cost of revenue553000300000
Gross profit5−5−3000115−10000
111374534316,768641
Research & development48435332161−1
56534241−1332
Selling & marketing000000000000
General & administrative56534241−1332
Other expenses20—−2−3−2−3016,768−30−1
Operating income−16−13−10−6−8−4312−10−9−4−1
000−1332−1−5−661
Interest income000000000000
Other non-operating income−80—00−30000−30
Income before tax−16−13−10−714−1−211−15−152−1
Income tax expense000000000000
Net income from continuing operations—5812−3−1−211−15−152−1
Net income—5812−3−1−211−15−152−1
EPS, basic−$0.01−$0.04−$0.05−$0.03−$0.00−$0.00−$0.01$6.55−$4.65−$6.67$0.41−$0.09
EPS, diluted−$0.01−$0.04−$0.05−$0.03−$0.00−$0.00−$0.01$6.55−$4.65−$6.67$0.41−$0.09
Weighted average shares, basic1,587125137144922342342342255
Weighted average shares, diluted1,587125137144922342342342255
EBITDA−9−13—−5−8−5−512−10−8—−1
Depreciation & amortization000000000000
EBIT−9−9−10−6−8−5312−10−9—−1